Jean-Charles Soria to France
This is a "connection" page, showing publications Jean-Charles Soria has written about France.
Connection Strength
0.204
-
[New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge]. Med Sci (Paris). 2017 Jun-Jul; 33(6-7):563-564.
Score: 0.053
-
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer. 2011 Oct; 47(15):2249-55.
Score: 0.034
-
Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. Cancer Cell. 2021 08 09; 39(8):1039-1041.
Score: 0.017
-
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France. ESMO Open. 2021 06; 6(3):100134.
Score: 0.017
-
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. Eur Respir J. 2018 10; 52(4).
Score: 0.014
-
Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience. Eur J Cancer. 2018 07; 98:17-22.
Score: 0.014
-
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018 05; 19(5):649-659.
Score: 0.014
-
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018 03; 91:21-29.
Score: 0.014
-
Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer. 2017 09; 82:34-44.
Score: 0.013
-
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016 Apr 02; 387(10026):1415-1426.
Score: 0.012